How trash becomes treasure in biotech
Attenua’s plans didn’t exactly work out. The company raised $35 million in 2018 to see whether some repurposed drugs could treat chronic cough. It turns out they could not, which is likely why Attenua’s website disappeared.
But CODA Biotherapeutics didn’t see that as a dead end. As STAT’s Kate Sheridan reports, the company just paid an undisclosed sum for Attenua and its pipeline of once-failed therapies. CODA has no interest in cough. Instead, the company sees Attenua’s drugs as potential off-switches for gene therapy. And through that lens, their failure in prior human trials is a feature, not a bug.
“We said, well, let’s use one or two or three or four of these drugs that have been abandoned but have been vetted through hundreds of patients,” CODA CEO Mike Narachi said. “They’re safe molecules. As a category, thousands and thousands of patients have been exposed to these drugs.”
Read more.
But CODA Biotherapeutics didn’t see that as a dead end. As STAT’s Kate Sheridan reports, the company just paid an undisclosed sum for Attenua and its pipeline of once-failed therapies. CODA has no interest in cough. Instead, the company sees Attenua’s drugs as potential off-switches for gene therapy. And through that lens, their failure in prior human trials is a feature, not a bug.
“We said, well, let’s use one or two or three or four of these drugs that have been abandoned but have been vetted through hundreds of patients,” CODA CEO Mike Narachi said. “They’re safe molecules. As a category, thousands and thousands of patients have been exposed to these drugs.”
Read more.
.png)
No hay comentarios:
Publicar un comentario